Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBITDA (2016 - 2025)

Historic EBITDA for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $36.2 million.

  • Ani Pharmaceuticals' EBITDA rose 27661.68% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 51557.15%. This contributed to the annual value of $8.0 million for FY2024, which is 8534.27% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EBITDA of $36.2 million as of Q3 2025, which was up 27661.68% from $13.9 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' EBITDA peaked at $36.2 million during Q3 2025, and registered a low of -$23.7 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was $3.0 million (2021), whereas its average is $2.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 155450.64% in 2021, then surged by 45931.93% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' EBITDA (Quarter) stood at -$23.7 million in 2021, then surged by 107.67% to $1.8 million in 2022, then surged by 269.56% to $6.7 million in 2023, then tumbled by 165.09% to -$4.4 million in 2024, then surged by 927.78% to $36.2 million in 2025.
  • Its last three reported values are $36.2 million in Q3 2025, $13.9 million for Q2 2025, and $26.2 million during Q1 2025.